Cryosite Limited
Cryosite Limited Fundamental Analysis
Cryosite Limited (CTE.AX) shows strong financial fundamentals with a PE ratio of 24.47, profit margin of 13.87%, and ROE of 72.82%. The company generates $0.0B in annual revenue with strong year-over-year growth of 11.93%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 44.7/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CTE.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakCTE.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCTE.AX trades at attractive valuation levels.
Growth Score
ModerateCTE.AX shows steady but slowing expansion.
Financial Health Score
WeakCTE.AX carries high financial risk with limited liquidity.
Profitability Score
WeakCTE.AX struggles to sustain strong margins.
Key Financial Metrics
Is CTE.AX Expensive or Cheap?
P/E Ratio
CTE.AX trades at 24.47 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, CTE.AX's PEG of 1.55 indicates fair valuation.
Price to Book
The market values Cryosite Limited at 14.81 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.62 times EBITDA. This signals the market has high growth expectations.
How Well Does CTE.AX Make Money?
Net Profit Margin
For every $100 in sales, Cryosite Limited keeps $13.87 as profit after all expenses.
Operating Margin
Core operations generate 18.84 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $72.82 in profit for every $100 of shareholder equity.
ROA
Cryosite Limited generates $8.23 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cryosite Limited produces operating cash flow of $2.23M, showing steady but balanced cash generation.
Free Cash Flow
Cryosite Limited generates weak or negative free cash flow of $-1.70M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.03 in free cash annually.
FCF Yield
CTE.AX converts -3.18% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
24.47
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.55
vs 25 benchmark
P/B Ratio
Price to book value ratio
14.81
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.39
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.44
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.49
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.73
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.19
vs 25 benchmark
How CTE.AX Stacks Against Its Sector Peers
| Metric | CTE.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 24.47 | 28.45 | Better (Cheaper) |
| ROE | 72.82% | 763.00% | Weak |
| Net Margin | 13.87% | -45265.00% (disorted) | Strong |
| Debt/Equity | 2.44 | 0.34 | Weak (High Leverage) |
| Current Ratio | 0.49 | 2795.60 | Weak Liquidity |
| ROA | 8.23% | -16588.00% (disorted) | Weak |
CTE.AX outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cryosite Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
51.93%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
22.20%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
51.68%
Industry Style: Defensive, Growth, Innovation
High Growth